Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr-Jun;79(2):375-86.
doi: 10.3797/scipharm.1101-22. Epub 2011 Apr 10.

Physicochemical characterization and dissolution properties of meloxicam-gelucire 50/13 binary systems

Mahmoud El-Badry  1
Affiliations

Physicochemical characterization and dissolution properties of meloxicam-gelucire 50/13 binary systems

Mahmoud El-Badry. Sci Pharm. 2011 Apr-Jun.

Abstract

A solid dispersion of Meloxicam (MX), a poorly soluble, non steroidal anti-inflammatory drug, and Gelucire 50/13 was prepared by spray drying. Spherical microparticles were yielded with smooth surfaces as observed by scanning electron microscopy. According to differential scanning calorimetry and powder X-ray diffractometry analysis, MX was transformed from the crystalline state to the amorphous state as confirmed by the disappearance of its melting peak and the crystalline peaks. The dissolution tests at pH 7.4 revealed that the dissolution rate of encapsulated MX was 2.5-fold higher than that of the corresponding physical mixture and fourfold higher than the drug alone, respectively. The microparticles prepared at a ratio of 1:4 (drug/Gelucire) exhibited a 4-fold higher anti-inflammatory activity on the paw edema of rats in comparison to the drug alone. All in all, this work reveals that spray drying is a suitable technique for preparation of solid dispersions with improved biopharmaceutical and pharmacological characteristics of MX.

Keywords: Anti-inflammatory activity; Dissolution; Meloxicam; Powder X-ray diffractometry analysis; Scanning electron microscopy; Solid dispersion; Spray drying.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
SEM images of meloxicam (A), Gelucire 50/13 (B), physical mixture Gelucire/meloxicam 1:4 (C), solid dispersion Gelucire/meloxicam 1:1 (D) and solid dispersion Gelucire/meloxicam 1:4 (E).
Fig. 2.
Fig. 2.
Differential scanning calorimetry of MX (drug), Gelucire (gelu) its physical mixture (PM) and spray dried microparticles (SD) at different ratios of MX/Gelucire (w/w).
Fig. 3.
Fig. 3.
X-ray diffraction of MX (drug), Gelucire (gelu), its physical mixture (PM) and spray dried microparticles (SD) at different ratios of MX/Gelucire (w/w).
Fig. 4.
Fig. 4.
Dissolution profile of MX in 0.1 N HCL from its powder, PM and SDs of MX and Gelucire 50/13.
Fig. 5.
Fig. 5.
Dissolution profile of MX in 0.2 M phosphate buffer pH 7.4 from its powder, PM and SDs of MX and Gelucire 50/13.
Fig. 6.
Fig. 6.
The anti-inflammatory activity of MX and its PM 1:4, SD 1:1 as well as SD 1:4 microparticles.
See this image and copyright information in PMC

References

    1. Luger P, Daneck K, Engel W, Trummlitz G, Wagnar K. Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci. 1996;4:175–187. doi: 10.1016/0928-0987(95)00046-1. - DOI
    1. Hanft G, Turck D, Scheuerer S, Sigmund R. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflamm Res. 2001;50:35–37. doi: 10.1007/PL00000219. - DOI - PubMed
    1. Martinez M, Viota-Gallardo J, Benavides M, Lopez-Duran J, Visitacion L. Rheological behavior of gels and meloxicam release. Int J Pharm. 2007;333:17–23. doi: 10.1016/j.ijpharm.2006.09.045. - DOI - PubMed
    1. Gupta SK, Bansal P, Bhadwaj RK, Jaiswal J, Velpandian T. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gel in animal models: pharmacokinetic parameters after topical application. Skin Pharmacol Appl Skin Physiol. 2002;15:105–111. doi: 10.1159/000049397. - DOI - PubMed
    1. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The “high solubility” definition of the current FDA guidance on biopharmaceutical classification System may be too strict for acidic drugs. Pharm Res. 2004;21:293–299. doi: 10.1023/B:PHAM.0000016242.48642.71. - DOI - PubMed

LinkOut - more resources